2017 Symposium

2016 Symposium

2015 Symposium

2015 Agenda and Bios

2015 Symposium Photos

2014 Symposium

2014 Agenda and Bios

2013 Featured Talks

2013 Symposium Photos

Previous Symposia

2016 Featured Talks » Targeting the PI3K-mTOR signaling circuitry in cancer: a bridge from bench to clinic



Targeting the PI3K-mTOR signaling circuitry in cancer: a bridge from bench to clinic


J. Silvio Gutkind, PhD
Moores Cancer Center








J. Silvio Gutkind, PhD
Professor of Pharmacology
UC San Diego Moores Cancer Center


Dr. Gutkind received his PhD in pharmacy and biochemistry from the University of Buenos Aires, Argentina, and after his post-doctoral training at the NIMH and NCI, he joined the NIDCR, NIH, as chief of the Oral and Pharyngeal Cancer Branch. At the NIH, he led a national and international effort addressing oral and head and neck malignancies until his recent recruitment as Professor, Department of Pharmacology, and Associate Director of Basic Science, UC San Diego Moores Cancer Center. Dr. Gutkind’s research team studies the molecular basis of cancer, with emphasis on basic mechanisms of signal transduction and cell growth control and their dysregulation in human malignancies, with emphasis on oral squamous cell carcinogenesis, AIDS-malignancies, and uveal and cutaneous melanoma. The goal of his research program is to exploit the emerging information on dysregulated signaling circuitries and individual genomic and molecular alterations to identify new mechanism-based precision therapies to prevent and treat cancer. In particular, Dr. Gutkind has recently led a multi-institutional effort aimed at exploring the biochemical consequences and clinical benefits of treating newly diagnosed head and neck cancer patients with mTOR inhibitors. As part of a new multidisciplinary team at the Moores Cancer Center, he is now investigating the effectiveness and mechanism of action of PI3K/mTOR inhibitors for oral cancer prevention and treatment, as single agents and as part of novel co-targeting strategies, and he is co-leading a new precision prevention medicine trial in oral premalignancy.